- Email: [email protected]
Correction to Lancet Oncol 2016; 17: 727–37
Corrections
Correction to Lancet Oncol 2016; 17: 727–37 Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17: 727–37—In Figure 1 of this Article, the number of patients who withdrew after randomisation should have been 1 in the delayed ADT group and 2 in the immediate ADT group. This correction has been made to the online version as of July 28, 2017.
www.thelancet.com/oncology Published online July 28, 2017 http://dx.doi.org/10.1016/S1470-2045(17)30575-2
Lancet Oncol 2017 Published Online July 28, 2017 http://dx.doi.org/10.1016/ S1470-2045(17)30575-2
1
Correction to Lancet Oncol 2016; 17: 727–37 Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17: 727–37—In Figure 1 of this Article, the number of patients who withdrew after randomisation should have been 1 in the delayed ADT group and 2 in the immediate ADT group. This correction has been made to the online version as of July 28, 2017.
www.thelancet.com/oncology Published online July 28, 2017 http://dx.doi.org/10.1016/S1470-2045(17)30575-2
Lancet Oncol 2017 Published Online July 28, 2017 http://dx.doi.org/10.1016/ S1470-2045(17)30575-2
1